7uap Citations

Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.

Abstract

SARS-CoV-2 infection or vaccination produces neutralizing antibody responses that contribute to better clinical outcomes. The receptor-binding domain (RBD) and the N-terminal domain (NTD) of the spike trimer (S) constitute the two major neutralizing targets for antibodies. Here, we use NTD-specific probes to capture anti-NTD memory B cells in a longitudinal cohort of infected individuals, some of whom were vaccinated. We found 6 complementation groups of neutralizing antibodies. 58% targeted epitopes outside the NTD supersite, 58% neutralized either Gamma or Omicron, and 14% were broad neutralizers that also neutralized Omicron. Structural characterization revealed that broadly active antibodies targeted three epitopes outside the NTD supersite including a class that recognized both the NTD and SD2 domain. Rapid recruitment of memory B cells producing these antibodies into the plasma cell compartment upon re-infection likely contributes to the relatively benign course of subsequent infections with SARS-CoV-2 variants, including Omicron.

Articles - 7uap mentioned but not cited (5)

  1. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, Bowen AD, Liu M, Wang M, Yu J, Valdez R, Lauring AS, Sheng Z, Wang HH, Gordon A, Liu L, Ho DD. Cell 186 279-286.e8 (2023)
  2. Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins. Wang Z, Muecksch F, Cho A, Gaebler C, Hoffmann HH, Ramos V, Zong S, Cipolla M, Johnson B, Schmidt F, DaSilva J, Bednarski E, Ben Tanfous T, Raspe R, Yao K, Lee YE, Chen T, Turroja M, Milard KG, Dizon J, Kaczynska A, Gazumyan A, Oliveira TY, Rice CM, Caskey M, Bieniasz PD, Hatziioannou T, Barnes CO, Nussenzweig MC. Immunity 55 998-1012.e8 (2022)
  3. Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2. Wang Q, Li Z, Guo Y, Mellis IA, Iketani S, Liu M, Yu J, Valdez R, Lauring AS, Sheng Z, Gordon A, Liu L, Ho DD. iScience 26 108254 (2023)
  4. Comprehensive structural analysis reveals broad-spectrum neutralizing antibodies against SARS-CoV-2 Omicron variants. Chi X, Xia L, Zhang G, Chi X, Huang B, Zhang Y, Chen Z, Han J, Wu L, Li Z, Sun H, Huang P, Yu C, Chen W, Zhou Q. Cell Discov 9 37 (2023)
  5. Neutralization and Stability of JN.1-derived LB.1, KP.2.3, KP.3 and KP.3.1.1 Subvariants. Li P, Faraone JN, Hsu CC, Chamblee M, Liu Y, Zheng YM, Xu Y, Carlin C, Horowitz JC, Mallampalli RK, Saif LJ, Oltz EM, Jones D, Li J, Gumina RJ, Bednash JS, Xu K, Liu SL. bioRxiv 2024.09.04.611219 (2024)


Reviews citing this publication (15)

  1. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Chen Y, Zhao X, Zhou H, Zhu H, Jiang S, Wang P. Nat Rev Immunol 23 189-199 (2023)
  2. Antibody-mediated neutralization of SARS-CoV-2. Gruell H, Vanshylla K, Weber T, Barnes CO, Kreer C, Klein F. Immunity 55 925-944 (2022)
  3. Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity. Aguilar-Bretones M, Fouchier RA, Koopmans MP, van Nierop GP. J Clin Invest 133 e162192 (2023)
  4. Protective neutralizing epitopes in SARS-CoV-2. Liu H, Wilson IA. Immunol Rev 310 76-92 (2022)
  5. Role of the humoral immune response during COVID-19: guilty or not guilty? Yaugel-Novoa M, Bourlet T, Paul S. Mucosal Immunol 15 1170-1180 (2022)
  6. Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies. Huang Q, Han X, Yan J. Emerg Microbes Infect 11 2412-2422 (2022)
  7. Antibody-mediated immunity to SARS-CoV-2 spike. Errico JM, Adams LJ, Fremont DH. Adv Immunol 154 1-69 (2022)
  8. SARS-CoV-2 epitopes inform future vaccination strategies. Shafqat A, Omer MH, Ahmad O, Niaz M, Abdulkader HS, Shafqat S, Mushtaq AH, Shaik A, Elshaer AN, Kashir J, Alkattan K, Yaqinuddin A. Front Immunol 13 1041185 (2022)
  9. Turning point: A new global COVID-19 wave or a signal of the beginning of the end of the global COVID-19 pandemic? Ding K, Jiang W, Xiong C, Lei M. Immun Inflamm Dis 10 e606 (2022)
  10. Biological Actions, Implications, and Cautions of Statins Therapy in COVID-19. Liu C, Yan W, Shi J, Wang S, Peng A, Chen Y, Huang K. Front Nutr 9 927092 (2022)
  11. Humoral immunity for durable control of SARS-CoV-2 and its variants. Kotaki R, Moriyama S, Takahashi Y. Inflamm Regen 43 4 (2023)
  12. Neutralizing and enhancing antibodies against SARS-CoV-2. Liu Y, Arase H. Inflamm Regen 42 58 (2022)
  13. SARS-CoV-2 S Glycoprotein Stabilization Strategies. Pedenko B, Sulbaran G, Guilligay D, Effantin G, Weissenhorn W. Viruses 15 558 (2023)
  14. Status and Developing Strategies for Neutralizing Monoclonal Antibody Therapy in the Omicron Era of COVID-19. Ren Z, Shen C, Peng J. Viruses 15 1297 (2023)
  15. Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review). Zhang T, Yang D, Tang L, Hu Y. Mol Med Rep 30 148 (2024)

Articles citing this publication (46)